temsirolimus · Pf Prism Cv · NDA 022088
Torisel
Earliest generic entry, as listed
10 Nov 2032
Blocked by patent: US 8791097.
Listed patents · 3 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 8791097 | — | 10 Nov 2032 |
| US 8791097 | use U-1551 | 10 May 2032 |
| US 8791097 | use U-1550 | 10 May 2032 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 022088 · 001 · RLD | solution, intravenous | 25MG/ML (25MG/ML) | 10 Nov 2032 |
Expired or delisted (2)
- US 8026276 · — · 20 Jul 2026
- US 8026276 · product · 20 Jan 2026